ArticleInternational journal of chronic obstructive pulmonary disease
The Impact of Exacerbation Frequency on Clinical and Economic Outcomes in Swedish COPD Patients: The ARCTIC Study.
Article in International journal of chronic obstructive pulmonary disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- InhaledEuropean respiratory review : an official journal of the European Respiratory Society · 2024Pooled it
- Cardiovascular and mortality risks following COVID-19-related versus non-COVID-19-related chronic obstructive pulmonary disease exacerbations.Annals of the American Thoracic Society · 2026Article
- Impact of a follow-up visit on two-year mortality after severe exacerbation of COPD in Finland.European clinical respiratory journal · 2026Article
- A qualitative study of patient experiences and expectations around hospital care during exacerbations of chronic obstructive pulmonary disease - a health CASCADE study.BMC pulmonary medicine · 2025Article
- Delaying disease progression in COPD with early escalation to triple therapy: a modelling study (DEPICT-2).ERJ open research · 2025Article
- Diffusion capacity and static hyperinflation as markers of disease progression predict 3-year mortality in COPD: Results from COSYCONET.Respirology (Carlton, Vic.) · 2025Observational
- The Burden of COPD with Type 2 Inflammation in North-West Continental Europe.International journal of chronic obstructive pulmonary disease · 2025Review
- Clinical and Paraclinical Characteristics and Predictive Factors of Chronic Obstructive Pulmonary Exacerbation.Materia socio-medica · 2025Article
- The DOSE index in chronic obstructive pulmonary disease: evaluating healthcare costs.BMC pulmonary medicine · 2024Article
- Extracellular Water Ratio and Phase Angle as Predictors of Exacerbation in Chronic Obstructive Pulmonary Disease.Advances in respiratory medicine · 2024Article
- Effect of Broncho-Vaxom (OM-85) on the frequency of chronic obstructive pulmonary disease (COPD) exacerbations.BMC pulmonary medicine · 2023Article
- DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach.Advances in therapy · 2023Article
- The Clinical Characteristics and Outcomes in Non-Frequent Exacerbation Patients with Chronic Obstructive Pulmonary Disease in the Chinese Population.International journal of chronic obstructive pulmonary disease · 2023Article
- Lack of COPD-Related Follow-Up Visits and Pharmacological Treatment in Swedish Primary and Secondary Care.International journal of chronic obstructive pulmonary disease · 2022Article
- Treatment Patterns, Socioeconomic Status and Clinical Burden in Mild COPD: A Swedish Real-World, Retrospective Cohort Study, the ARCTIC Study.International journal of chronic obstructive pulmonary disease · 2022Article
- Neutrophil-to-lymphocyte ratio, blood eosinophils and COPD exacerbations: a cohort study.ERJ open research · 2021Article
- Disease Trajectories and Impact of One Moderate Exacerbation in Gold B COPD Patients.International journal of chronic obstructive pulmonary diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study was to assess the association between exacerbation frequency and clinical and economic outcomes in patients with COPD. PATIENTS AND
methodsElectronic medical record data linked to National Health Registries were collected from COPD patients at 52 Swedish primary care centers (2000-2014). The outcomes analyzed were exacerbation rate, mortality, COPD treatments, lung function and healthcare costs during the follow-up period. Based on the exacerbation rate two years before index date, the patients were initially classified into three groups, either 0, 1 or ≥2 exacerbations per year. After the index date, the classification into exacerbation groups was updated each year based on the exacerbation rate during the last year of follow-up. A sensitivity analysis was conducted excluding patients with asthma diagnosis from the analysis.
resultsIn total 18,586 COPD patients were analyzed. A majority of the patients (60-70%) who either have had no exacerbation or frequent exacerbations (≥2/year) during the pre-index period remained in their group (ie, with 0 or ≥2 annual exacerbations) during up to 11 years of follow-up. Compared with having no exacerbation, mortality was higher in patients having 1 (HR; 2.06 [1.93-2.20]) and ≥2 (4.58 [4.33-4.84]) exacerbations at any time during the follow-up. Lung function decline was more rapid in patients with frequent exacerbations and there was an almost linear relationship between exacerbations frequency and mortality. Total healthcare costs were higher in the frequent exacerbation group (≥2/year) than in patients with no or one exacerbation annually (p<0.0001 for both). The results did not differ from the main analysis after exclusion of patients with a concurrent asthma diagnosis.
conclusionIn addition to faster lung function decline and increased mortality, frequent exacerbations in COPD patients imply a significant economic burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.